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Table 1
Prevalence of OA divided by subgroups of OA
PFOA TFOA COA No radiographic OA Total
Baseline 83 0 0 629 712
2 year 51 53 68 547 719
5 year 76 73 86 468 703
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A42but not in Tlr2 null cells (0.9-fold, p¼0.5), suggesting that these effects
are mediated through TLR2. DRG cells also respond to a synthetic TLR2
ligand (Pam3CSK4, 10 mM, 7.7-fold, p<0.001), providing additional
evidence that TLR2 signaling can lead to MCP-1 upregulation.
Conclusions: These studies suggest that, through TLR2, nociceptors
have the ability to respond to a speciﬁc 32-mer cleavage product of
aggrecan. This pathway may play a role in the development of osteo-
arthritis-associated pain.
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Purpose: Excessive mechanical stress loading on articular cartilage is
one of the major factors of osteoarthritis (OA); however, the molecular
mechanisms of cartilage degradation by such loading remain unclear.
The present study therefore analyzed gene expression proﬁles of
articular chondrocytes under mechanical stress loading and inves-
tigated functions of the candidate gene.
Methods: We applied an uni-axial cyclic cell stretch (0.5 Hz, 10%
stretch, for 30 min) to primary articular chondrocytes obtained from
mouse knee joint by STB-140 (STREX), and performed cDNA micro-
array analysis using the samples before and after the loading. We also
applied excessive hydrostatic pressure (0.1 Hz, 20 MPa, for 30 min) to
3-week-old mouse femoral heads by a custom-made device, and
compared the results in both systems. The gene expressions were
conﬁrmed by real-time RT-PCR and immunohistochemistry. The
catabolic ability was assessed by measuring the concentration of
aggrecan released from cultured 3-week-old mouse femoral heads
using the dimethylmethylene blue dye-binding assay. We used mouse
primary articular chondrocytes and mouse chondrogenic cell line
ATDC5 for in vitro functional analyses. We further examined in vivo
effects of a candidate gene using a surgical OA model of mouse knee
joint.
Results: Microarray analyses revealed that 2,076 genes were increased
more than twice by the cell stretch. Among them, we focused on
Gremlin1 (Grem1), which is one of the most highly expressed genes.
Grem1 is known to be a secretory protein that regulates limb devel-
opment, although its function in articular cartilage is unknown.
Immunocytochemistry conﬁrmed that Grem1 protein was increased in
cytoplasm of articular chondrocytes by the cell stretch. Grem1 mRNA
expression was also increased in mouse femoral heads under exces-
sive cyclic hydrostatic pressure. Immunoﬂuorescence further revealed
that Grem1 protein was increased on the cell surface of articular
chondrocytes during OA development of the mouse model. In primary
culture of mouse articular chondrocytes, recombinant human (rh)
GREM1 treatment or adenoviral overexpression of Grem1 induced the
expressions of catabolic factors including Mmp13 and Adamts5, and
suppressed those of anabolic factors including Col2a1, Aggrecan and
Sox9. Similar results were observed in ATDC5 by lentiviral trans-
duction of Grem1. Microarray analyses showed that other various
catabolic and inﬂammatory factors, such as Mmp3, Mmp8, Il1b (IL-1b),
and Il6 (IL-6), were signiﬁcantly upregulated by the rhGREM1 treat-
ment in mouse articular chondrocytes. In the organ culture of mouse
femoral heads, rhGREM1 treatment increased aggrecan release into
the medium in a dose-dependent manner. In the mouse OA model,
intra-articular injection of rhGREM1 exacerbated cartilage degrada-
tion. In contrast, intra-articular injection of Grem1 neutralizing anti-
body inhibited OA development.
We further found that Grem1 enhanced the NF-kB signaling activation
by luciferase assay. Notably, in the organ culture of femoral heads, the
increased aggrecan release by the rhGREM1 treatment was completely
cancelled by gene deletion of p65/Rela, or an IKK inhibitor (BMS-
345541) treatment, indicating that the catabolic effects of Grem1 were
mediated by the NF-kB signaling pathway.
Conclusions: Grem1 is induced by excessive mechanical stress loading,
and exerts catabolic effects on articular cartilage through the NF-kB
signaling pathway. Grem1 may be a novel therapeutic target of OA.31
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Purpose: Most research in osteoarthritis (OA) has focused on the
tibiofemoral (TF)-joint, although it is proposed that signs of patellofe-
moral (PFOA), opposed to TFOA, are associated with pain symptoms and
disability. Additionally, it is suggests that OA in the knee starts in the PF
joint and progresses to the TF joint. Therefore, this study addresses the
following aims: 1. Determine the prevalence and incidence of PFOA
compared to TFOA in patients with a recent onset of knee pain 2.
Describe the natural course of both PFOA and TFOA after 2 and 5 years
follow-up and 3. Identify if patients with PFOA have a different phe-
notype compared to patients with TFOA, or patients with combined
PFOA and TFOA.
Methods: For this study data of the Cohort Hip and Cohort Knee
study (CHECK) were used (n¼ 1002). Patients with early OA symp-
toms of the knee were selected. All patients completed a ques-
tionnaire and underwent physical examination at baseline and after 2
and 5 years follow-up. At each time-point, three radiographs of the
knee were obtained (Anterior-Posterior, skyline and lateral). Follow-
ing these radiographs, all patients were classiﬁed into four different
groups: isolated TFOA, isolated PFOA, combined (TF and PF) OA (COA)
or no radiographic OA. Only the knee with most severe symptoms
per patient was analyzed. Multivariate backward stepwise binary
logistic regression (p<.05) was used to identify if patient character-
istics and characteristics from physical examination were associated
with a speciﬁc group of OA patients. The following variables were
included in the regression analyses: gender, age, body mass index
(BMI), baseline pain, bony tenderness during palpation, crepitus in
the knee duration ﬂexion, degrees of knee ﬂexion, patellar grinding
test.
Results: The total cohort comprised 845 patients (80% females) with a
mean age of 55.3 (5.18) years. The prevalence and incidence of the
different types of OA are presented in Table 1. At baseline the majority
of patients had no radiographic signs of OA. The natural course of the
different patient subgroups is presented in Figure 1. Twenty-seven out
of the 83 patients who had PFOA at baseline remained to have PFOA
at 5 years follow-up; 56 developed COA after two to ﬁve yours follow-
up.
Patients with PFOA at baseline were more likely to have a higher BMI
(OR (95%CI) 1.09 (1.03;1.16), higher age (1.07 (1.01;1.13), positive
patellar grinding test (1.92 (1.12;3.29) and palpable bony tenderness
of the knee (2.90 (1.09;7.76) compared to patients without radio-
graphic OA at baseline. After two years, patients with PFOA did not
differ from patients with TFOA, however patients with PFOA, had
lower BMI scores at baseline compared to patients with COA (OR (95%
CI) 0.90 (0.82;0.99).However no differences were seen after ﬁve
year follow-up. Patients with signs of PFOA at baseline who did
not develop COA after 5 years had signiﬁcantly higher active knee
ﬂexion range of motion (ROM), compared to patients who had PFOA
at baseline and developed COA at follow-up (OR (95%CI) 1.10
(1.01;1.20).
Conclusions: After 5 years follow-up 33% of the primary care patients
with knee pain had developed OA (PFOA, TFOA or COA). About one third
of the patients with PFOA still have PFOA after 5 years and these
patients distinguish in a high active knee ﬂexion ROM. Patients with
PFOA at baseline signiﬁcantly differ from patients without any signs of
radiographic OA at baseline. However phenotypes of patients with
PFOA do not seem to differ from patients with TFOA or COA.
